Hologic, Inc.
HOLX Healthcare Medical - Instruments & Supplies NASDAQ
$75.74
$-0.01 (-0.01%)
Open: $75.50 | High: $75.75 | Low: $75.49 | Prev Close: $75.75
Market Cap: $16.91B
Volume: 3.1M | Avg: 2.7M
Last updated: March 09, 2026 at 02:02 AMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 625
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 31.43 |
| P/B Ratio | 3.24 |
| P/S Ratio | 4.10 |
| EPS | $2.41 |
| Beta | 0.73 |
| Shares Outstanding | 223.24M |
| 52-Week High | $75.75 |
| 52-Week Low | $51.90 |
| SMA 50 | $75.03 |
| SMA 200 | $69.93 |
| Next Earnings | April 30, 2026 09:00 PM ET |
Financial Ratios
| Gross Margin | 52.8% |
| Operating Margin | 17.5% |
| Net Margin | 13.2% |
| ROE | 11.0% |
| ROA | 5.9% |
| Debt/Equity | 0.48 |
| Current Ratio | 4.04 |
| Quick Ratio | 3.32 |
Balance Sheet
| Total Assets | $9.01B |
| Total Liabilities | $3.97B |
| Total Equity | $5.05B |
|
|
|
| Cash | $1.96B |
| Total Debt | $2.63B |
| Net Debt | $667.30M |
Income Statement
| Revenue | $4.10B |
| Gross Profit | $2.50B |
| Operating Income | $714.30M |
| Net Income | $565.70M |
|
|
|
| EBITDA | $1.02B |
| Revenue/Share | $18.39 |
Cash Flow
| Operating CF | $1.06B |
| CapEx | $137.00M |
| Free Cash Flow | $920.10M |
|
|
|
| Book Value/Share | $23.37 |
| Tangible Book/Share | $4.69 |
| Equity/Share | $23.37 |
Technical Indicators
| RSI (14) | 81.50 Overbought |
| MACD |
0.15
Signal: 0.12
|
| Volatility | 2.12% |
| Trading Signal | Overbought |
Performance & Returns
| 1 Year | +34.22% |
| Sharpe Ratio | 1.47 Good |
| Volatility (Ann.) | 23.94% Moderate |
| HOLX (1Y) | +34.22% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | +21.19% |
Sector Comparison (Healthcare)
| Metric | HOLX | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 31.43 | 27.58 | 66% |
| P/B Ratio | 3.24 | -19.58 | 57% |
| ROE (%) | 11.01% | -9.50% | 43% |
| Net Margin (%) | 13.18% | 9.24% | 55% |
| Stock Score | 625 | 542.0 | 87% |
| 1Y Return (%) | +34.22 % | +7.63 % | 81% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HOLX | $75.74 | $75.49 | $75.42 | $75.38 | $75.04 | $69.93 | 81.50 | 0.15 | 2.12% | 1144363 | Strong Long | Bullish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the HOLX stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| HOLX | What Drives Hologic's GYN Surgical Strength in a Competitive Market? | Neutral | zacks.com | Read More |
| HOLX | Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock | Neutral | zacks.com | Read More |
| HOLX | Hologic's Diagnostics Strength in Focus: Is More Upside Ahead? | Neutral | zacks.com | Read More |
| HOLX | Becker Capital Management Inc. Boosts Holdings in Hologic, Inc. $HOLX | Neutral | defenseworld.net | Read More |
| HOLX | 111 Capital Lowers Stock Holdings in Hologic, Inc. $HOLX | Neutral | defenseworld.net | Read More |
Recent Insider Trading
| Date | Insider | Position | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-02-27 | Liddy Anne M. | officer: General Counsel | SELL | 185 | $75.36 | $13942 |
Company Information
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
| CEO | Stephen MacMillan |
| Employees | 7063 |
| Country | US |
| IPO Date | 1990-03-01 |
| Exchange | NASDAQ |
| Website | https://www.hologic.com |
| Sector | Healthcare |
| Industry | Medical - Instruments & Supplies |
Similar Stocks (Healthcare - Medical - Instruments & Supplies)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category